Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-017240

Executive VP, Head of R&D gave up 1,563 shares (to pay taxes)

  • Executive VP, Head of R&D acquired 3,333 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2020-03-05 Option exercise +3,333 49,168 D
Ho Tony W Executive VP, Head of R&D 2020-03-06 Shares withheld for taxes −1,563 $52.64 $82,276 47,605 D
Loading xslF345X03/doc4.xml…